Novo Nordisk stock slides as Lilly pressure and 5 million Wegovy pill prescriptions draw attention
Published on 08/13/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock is under pressure as Eli Lilly competition and the Wegovy pill's 5 million-plus U.S. prescriptions keep the obesity franchise under a close investor spotlight. The shares last traded at $46.52 on August 12, 2026, and the stock's market cap was listed at $207.71 billion in same-day market data.
The latest reported quarter gives the debate a firmer base. In the second quarter of 2026, Novo Nordisk reported $11.98 billion in revenue and $0.94 in EPS, while net margin was 35.36% and return on equity reached 61.20%.
Competition is the driver
Recent reporting says Novo Nordisk's chief executive argued that the obesity drug market will not be winner-take-all, even as management acknowledged market-share gains by Lilly. The same coverage also pointed to uncertainty around pricing power and the valuation gap that has weighed on the shares.
A separate market snapshot shows the stock closed at $46.52 on August 12, 2026, and was trading at $45.53 in extended hours as of August 13, 2026, 7:31 a.m. ET. That puts the shares well below their recent peak and leaves the market focused on whether new prescription trends can offset the competitive pressure.
What the numbers say
The quantified comparison is stark: the company reported $11.98 billion in second-quarter revenue and $0.94 in EPS, while analysts were looking for $3.39 in full-year EPS for 2026. A broker note published on August 13, 2026, also put the average target price at 313.54 DKK versus a last close of 299.50 DKK on the home market.
That mix of current earnings, full-year expectations and a modest target premium keeps the shares tied to execution rather than to a simple multiple story. For investors, the key question is whether the next prescription data point can keep pace with Lilly's push in oral obesity treatment.
Wegovy pill remains central
Wegovy is the company's headline product in this debate, and management has said the pill has surpassed 5 million prescriptions in the United States. That scale matters because Novo Nordisk still derives most of its business from diabetes and obesity treatments, with rare disease products making up the remainder.
The product story is no longer just about launch momentum. It is now tied to pricing, competitive share and how quickly the franchise can convert prescription volume into durable earnings growth.
Shares and valuation
Novo Nordisk shares were last quoted at $46.52 on August 12, 2026, with extended trading at $45.53 as of August 13, 2026, 7:31 a.m. ET. Market data placed the company's value at $207.71 billion, giving investors a live reference point as the competitive narrative evolves.
More on Novo Nordisk
Wegovy is the weekly obesity treatment at the center of the current debate, and the pill format has widened the franchise beyond injections. Its prescription run-rate is now one of the clearest gauges of whether Novo Nordisk can defend its position against Lilly.
Investor relations
Novo Nordisk A/S remains one of the most closely watched large-cap healthcare names in Europe and the US ADR market. The stock's next move will likely depend on whether prescription growth and margin delivery can keep pace with the competitive backdrop.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0060534915
Ticker: NVO
Exchange: NYSE
Price: $46.52
As of: August 12, 2026, 3:58 p.m. ET
Market cap: $207.71 billion
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: S&P 500
Next earnings date: August 14, 2026
